Pacer Advisors, Inc. Celldex Therapeutics, Inc. Transaction History
Pacer Advisors, Inc.
- $38.6 Billion
- Q1 2024
A detailed history of Pacer Advisors, Inc. transactions in Celldex Therapeutics, Inc. stock. As of the latest transaction made, Pacer Advisors, Inc. holds 890 shares of CLDX stock, worth $32,938. This represents 0.0% of its overall portfolio holdings.
Number of Shares
890Holding current value
$32,938% of portfolio
0.0%Shares
4 transactions
Others Institutions Holding CLDX
# of Institutions
207Shares Held
61.2MCall Options Held
291KPut Options Held
246K-
Wellington Management Group LLP Boston, MA7.65MShares$283 Million0.06% of portfolio
-
Black Rock Inc. New York, NY4.51MShares$167 Million0.0% of portfolio
-
Vanguard Group Inc Valley Forge, PA3.65MShares$135 Million0.0% of portfolio
-
Eventide Asset Management, LLC Boston, MA3.12MShares$115 Million2.11% of portfolio
-
Price T Rowe Associates Inc Baltimore, MD3.09MShares$114 Million0.02% of portfolio
About Celldex Therapeutics, Inc.
- Ticker CLDX
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 46,772,400
- Market Cap $1.73B
- Description
- Celldex Therapeutics, Inc., a biopharmaceutical company, engages in developing therapeutic monoclonal and bispecific antibodies for the treatment of various diseases. Its drug candidates include antibody-based therapeutics to treat patients with inflammatory diseases and various forms of cancer. The company's clinical development programs CDX-01...